This pilot study evaluates a novel wearable apnoea detection device (WADD) designed to overcome the limitations of current apnoea monitoring technologies. The device is small, wireless, and non-intrusive, measuring just 3.74×2.4×2.1 cm and weighing only 17 grams. It is attached to the neck using hydrocolloid adhesive patches and detects breathing-related turbulence in the trachea via a custom acoustic chamber. A proprietary signal processing algorithm analyzes temporal and frequency characteristics of the detected signal, dynamically adapting to changes in the user and environment without requiring calibration or individualized settings.Penicillin-Streptomycin web
The study involved 20 healthy controls and 10 patients referred for sleep apnoea evaluation. Both WADD and the FDA-approved SOMNO clinical system were tested during normal sleep under identical conditions. Performance was assessed by comparing automated detections with blinded expert scoring across 62,727 ten-second epochs. For spontaneous apnoeas during natural sleep—using clinician scoring as the gold standard—the WADD achieved 88.6% sensitivity and 99.6% specificity. In contrast, the SOMNO system demonstrated only 14.3% sensitivity and 99.Silver(I) fluoride Epigenetics 3% specificity.PMID:35053560 When both apnoea and hypopnoea were considered together, the WADD maintained high performance with 77.1% sensitivity and 99.7% specificity, compared to 54% and 98.5% for SOMNO.
The device showed excellent resilience to artefacts, including movement, background noise, and posture changes, which commonly interfere with traditional systems. During instructed breath-holding exercises, WADD sensitivity reached up to 99.2%, with near-perfect specificity. Notably, it correctly identified all apnoeas lasting over 30 seconds and generated only three false positives in that category. Discrepancies between WADD and clinician classifications primarily arose when the device classified short hypopnoeas as apnoeas—expected given its design focus on apnoea detection rather than hypopnoea.
Participant comfort was significantly better with WADD, rated 5 out of 5 for both comfort and sleep quality, while SOMNO scored 3–4. Skin irritation from the adhesive was minimal, with no severe reactions reported. The device’s ability to differentiate between central and obstructive apnoea further enhances its clinical utility, with 90% accuracy for central events and 96% for obstructive ones.
These results indicate that WADD performs comparably to expert human scorers, even in complex real-world conditions with significant artefacts. Its portability, ease of use, high accuracy, and low discomfort make it a promising tool for home-based apnoea monitoring. While not a replacement for full polysomnography, it could serve as an effective triage instrument to identify candidates for specialist referral. Future studies should expand the sample size and validate performance across diverse populations and clinical scenarios.MedChemExpress (MCE) offers a wide range of high-quality research chemicals and biochemicals (novel life-science reagents, reference compounds and natural compounds) for scientific use. We have professionally experienced and friendly staff to meet your needs. We are a competent and trustworthy partner for your research and scientific projects.Related websites: https://www.medchemexpress.com